Product: D-Arginine, C₆H₁₄N₄O₂, CAS 157-06-2, molar mass 174.20 g mol⁻¹. The material is supplied as a white to off-white crystalline powder with a nitrogen content of 32.16% w/w. Industrial product models include the free-base crystalline powder, the hydrochloride salt, and Fmoc-protected derivatives for solid-phase peptide synthesis. The free base is preferred for nonaqueous peptide synthesis; the hydrochloride salt, CAS 627-75-8, molar mass 210.66 g mol⁻¹, is water-soluble and is selected when dissolution rate or buffering capacity is process-critical. The Cα stereocenter is in the R configuration, opposite to L-arginine. This inversion removes substrate activity at mammalian nitric oxide synthase and alters recognition by aminoacyl-tRNA synthetases. Lot release data for non-pharmacopeial reagent grade typically include assay by perchloric acid titration, chiral purity by ligand-exchange HPLC, water content by Karl Fischer, and residue on ignition; certificates should be obtained for each production lot rather than assumed.

Representative acceptance criteria for non-pharmacopeial reagent-grade D-arginine are shown below. These limits are not universal regulatory specifications; they should be tightened when the material enters GMP peptide drug manufacturing.

Does D-Arginine Participate in Nitric Oxide Synthase Reactions?

Recombinant endothelial NOS and inducible NOS assays demonstrate that D-arginine does not undergo measurable conversion to L-citrulline. Published radiochemical and fluorometric citrulline detection methods using calibrated standards show that D-arginine at 1 mM yields less than 0.5% of the L-arginine activity at the same concentration. This negative-control function is used in primary cell cultures and tissue homogenates to distinguish background from NADPH-dependent L-arginine oxidation. The assay requires centrifugal ultrafiltration with a 10 kDa molecular-weight cutoff membrane and separation of citrulline by reversed-phase HPLC with pre-column derivatization. Enzyme inhibition caused by trace L-arginine contamination in D-arginine lots can generate false-positive NOS activity; a chiral purity specification of ≥99.0% D-enantiomer is therefore linked directly to assay validity. High-performance liquid chromatography with a Crownpak CR(+) column, 5 µm, 150 mm × 4.0 mm i.d., using an aqueous perchloric acid mobile phase at pH 1.0–2.0 and UV detection at 200 nm is an adequate platform for lot acceptance. System suitability should meet resolution Rs ≥ 1.5 between D- and L-arginine peaks and tailing factor ≤ 1.5 in accordance with USP <621>.

When Chiral Purity Becomes Process-Critical in Peptide Synthesis

Automated solid-phase peptide synthesis using the Fmoc strategy couples Fmoc-D-Arg(Pbf)-OH after removal of the Nα-Fmoc group with 20% v/v piperidine in dimethylformamide. Coupling efficiency is lower when the Pbf-protected guanidino group is sterically hindered; double coupling with 2 equivalents of protected amino acid and 1.95 equivalents of HBTU plus 0.5 M N,N-diisopropylethylamine for 45 min at room temperature is a common protocol. Deprotection with trifluoroacetic acid, triisopropylsilane, and water (95:2.5:2.5 v/v/v) cleaves the peptide from the resin and removes Pbf. Process drift in water content above 0.5% w/w may lead to incomplete activation due to hydrolysis of the uronium coupling reagent. The free base is stored in a desiccator; the hydrochloride salt is not used for direct coupling because chloride can interfere with activation. For scale-up, resin loading is verified by Fmoc release at 290 nm using a UV-visible spectrophotometer. If enantiomeric purity of the D-Arg residue is critical, product should be used without prolonged storage in highly humid areas; moisture uptake above 1.0% w/w can accelerate deprotection side-reactions. Chiral purity after coupling is confirmed by acid hydrolysis (6 M HCl, 110 °C, 24 h) followed by Marfey’s derivatization and LC-MS.

Product model D-Arg-FB-98.5 differs from L-arginine and DL-arginine in Cα configuration, CAS registry, and biological recognition. L-arginine free base carries CAS 74-79-3; L-arginine hydrochloride carries CAS 1119-34-2; DL-arginine carries CAS 7200-25-1. The table below summarizes the distinctions relevant to incoming material inspection.

These differences affect raw material labelling and process selection. A material handler receiving D-arginine hydrochloride must not treat it as L-arginine hydrochloride because the two salts exhibit different optical rotation signs under matched polarimetric conditions; a rapid identity check should compare the signed rotation against the certificate rather than the absolute value. The free base and hydrochloride forms have different nitrogen contents and cannot be substituted on an equal-mass basis in peptide synthesis without correcting for the chloride and water content.

Chromatographic Resolution and Enantiomeric Excess Measurements

Enantiomeric excess of D-arginine is measured by chiral HPLC using ligand-exchange or zwitterionic chiral stationary phases. The Crownpak CR(+) column separates arginine enantiomers through a copper(II)-amino acid complex; the D-enantiomer is retained relative to the L-enantiomer under aqueous perchloric acid conditions. The method is limited by weak UV absorbance; detection at 200–210 nm requires a high-purity mobile phase to control baseline drift. For quantitative work, a reference standard of L-arginine is spiked at 0.1%, 0.5%, and 1.0% w/w into D-arginine to establish linearity; repeatability at 0.1% should have relative standard deviation below 10%. The limit of quantitation for L-arginine contamination is typically 0.05% w/w. Polarimetric methods may be used for rapid identity verification but are not suitable for low-level enantiomeric impurity because the measured rotation is a weighted average. If a lot passes HPLC chiral purity but fails optical rotation, the polarimeter cell temperature or concentration calculation must be checked; a 1 °C temperature change can shift rotation by approximately 0.2% to 0.5% depending on solvent and concentration. For salt forms, the chloride content is quantified by argentometric titration and should match the theoretical value of 16.84% w/w for the hydrochloride salt.

Freeze-drying D-arginine hydrochloride produces a partially amorphous salt.

Lyophilization of the hydrochloride from aqueous solution at a freezing rate below 1 °C min⁻¹ produces a mixture of crystalline hydrate and amorphous material, while higher cooling rates increase amorphous content and reduce reconstitution time. The glass transition temperature of fully amorphous D-arginine hydrochloride is not consistently reported in public literature; when product must be lyophilized, process development should use differential scanning calorimetry at 10 °C min⁻¹ and freeze-drying microscopy to identify collapse temperature rather than relying on published Tg values for L-arginine hydrochloride. Residual water after lyophilization should be below 1.0% w/w for microbial stability and below 0.5% w/w for formulation work requiring anhydrous salt. During scale-up, shelf temperature is held at -30 °C during primary drying and raised stepwise to 25 °C at a rate of 0.5 °C h⁻¹; chamber pressure is maintained at 50–100 µbar. This cycle is equipment-specific and must be verified by product temperature thermocouples.

Storage of the dried powder requires sealed polyethylene-lined aluminum foil bags. The free base is hygroscopic; repeated opening of bulk containers in a plant with relative humidity above 60% can increase water content by 0.2–0.5% w/w per eight-hour shift depending on particle size. Pre-drying at 60 °C under vacuum (≤10 mbar) for 4 h restores water content below 0.5% w/w for peptide synthesis. Avoid contact with strong oxidizers, nitrous acid, and nitrosating agents because secondary amine groups can form nitrosamines under acidic conditions; process equipment should be passivated stainless steel. The hydrochloride form is not recommended for direct solid-dose tableting under high-shear granulation because chloride stress corrosion cracking can occur in 316L stainless steel when the powder is in sustained contact with the metal at elevated humidity. Published data for this specific configuration is limited; operators should validate with material compatibility coupons. For trace metal control, inductively coupled plasma mass spectrometry after closed-vessel acid digestion is used; acceptance limits for lead, cadmium, arsenic, and mercury should follow ICH Q3D oral/inhalation options rather than compendial heavy metals tests when the material is used in pharmaceutical development.